[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100343711":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":30,"centralContacts":39,"locations":45,"responsibleParty":65,"collaborators":30,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":30,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":30,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":30,"overallStatus":47,"whyStopped":30,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Shinshu University","OTHER",[8,16,20],{"label":9,"type":10,"description":11,"interventionNames":12},"SERM plus ELD","ACTIVE_COMPARATOR","To examine the effects of SERM plus ELD in osteoporosis patients",[13,14,15],"Drug: SERM \"Viviant®Tablet 20mg\" and ELD \"Edirol®Tablet 0.75ug\"","Drug: Bisphosphonates and ELD \"Edirol®Tablet 0.75ug\"","Drug: ELD \"Edirol®Tablet 0.75ug\"",{"label":17,"type":10,"description":18,"interventionNames":19},"BP plus ELD","To examine the effects of BP plus ELD in osteoporosis patients",[13,14,15],{"label":21,"type":10,"description":22,"interventionNames":23},"ELD alone","To examine the effects of ELD alone in osteoporosis patients",[13,14,15],[25,31,35],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","SERM \"Viviant®Tablet 20mg\" and ELD \"Edirol®Tablet 0.75ug\"","To examine the effects of SERM and ELD in osteoporosis patients",[17,21,9],null,{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"Bisphosphonates and ELD \"Edirol®Tablet 0.75ug\"","To examine the effects of BP and ELD in osteoporosis patients",[17,21,9],{"type":26,"name":36,"description":37,"armGroupLabels":38,"otherNames":30},"ELD \"Edirol®Tablet 0.75ug\"","To examine the effects of ELD in osteoporosis patients",[17,21,9],[40],{"name":41,"role":42,"phone":43,"phoneExt":30,"email":44},"Yukio Nakamura","CONTACT","+81263372576","yxn14@aol.jp",[46],{"facility":41,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"RECRUITING","Matsumoto","Nagano","3908621","Japan","JP",{"type":54,"coordinates":55},"Point",[56,57],137.96667,36.23333,{"lat":57,"lon":56},[60,63],{"name":61,"role":42,"phone":62,"phoneExt":30,"email":44},"Yukio Nakamura, MD, PhD","+81-263-37-2659",{"name":61,"role":64,"phone":30,"phoneExt":30,"email":30},"PRINCIPAL_INVESTIGATOR",{"type":64,"investigatorFullName":41,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"Lecturer at Shinshu University School of Medicine","100343711","phase-2-examination-of-efficacy-and-safety-of-other-anti-resorption-drugs-after-2-year-denosumab-therapy-in-japanese-osteoporosis-patients-100343711",false,"NCT03755193","Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients","Examination of Efficacy and Safety of SERM or Bisphosphonates After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients","Inclusion Criteria:\n\n* osteoporosis patients\n\nExclusion Criteria:\n\n* not osteoporosis patients who are allergic to the drugs, refused to do this research, or who are pregnant","ALL","20 Years","120 Years",{"count":78,"type":79},90,"ESTIMATED","INTERVENTIONAL",[82],"PHASE2","The aim of this study is to examine the efficacy and adverse events in the following 3 groups in Japanese osteoporosis patients after 2-year-denosumab therapy:\n\nSERM and eldecalcitol treatment for 24 months Bisphosphonates and eldecalcitol treatment for 24 months Eldecalcitol treatment for 24 months",[85],"Osteoporosis","2021-09-20",{"date":88,"type":89},"2021-09-21","ACTUAL",{"date":91,"type":89},"2018-11-24",{"date":93,"type":79},"2026-11-23",{"name":5,"class":6},1]